Separating Contenders from Pretenders
The current M&A scramble is a strategic chess game. Giants like Novo Nordisk and Eli Lilly are looking over their shoulders at looming patent cliffs and need to buy innovation to protect their kingdoms. They are hunting for assets that are genuinely different, not just another ‘me-too’ drug with marginal benefits. They want novel delivery methods, better safety profiles, or drugs that work for specific patient groups.
For investors, this means the game is changing. The initial, indiscriminate excitement is likely to fade, replaced by a more discerning approach. The winners will be the companies with rock-solid clinical data, experienced leadership, and a realistic plan. Those relying on market hype and a slick PowerPoint presentation may find the phone stops ringing. The Metsera deal was the headline act, but the real story will be written by the companies that quietly deliver the goods. The opportunity is certainly there, but it requires a steady hand and a healthy dose of scepticism.
